Stock Events

Stock Events

CHMMD 

$0.100000
0
+$0.00+0% Friday 13:30

Statistics

Day High
-
Day Low
-
52W High
0.1
52W Low
0.1
Volume
-
Avg. Volume
0
Mkt Cap
410.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AugExpected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-0.16
-0.11
-0.05
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-258.5%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.61MRevenue
-6.75MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is involved in gene editing and CAR T-cell therapies, a direct competitor in gene-based cancer treatments.
Allogene Therapeutics
ALLO
Mkt Cap690.31M
Allogene Therapeutics focuses on allogeneic CAR T therapies for cancers, directly competing with Chimeric's technologies.
Precigen
PGEN
Mkt Cap1.9B
Precigen operates in the synthetic biology field developing CAR T therapies, competing in the same innovative cancer treatment sector.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR T-cell therapies, directly competing in the oncology segment.
Novartis
NVS
Mkt Cap293.94B
Novartis is a major player in the healthcare sector with successful commercial CAR T-cell therapies, competing on a global scale.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics engages in genomic medicine, including gene-edited cell therapies for cancer, competing in the advanced therapy sector.

About

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Show more...
CEO
Dr. Rebecca McQualter
Country
United States

Listings

AU
AU
CHM.AU
OTCM
US
CHMMD
OTC Link
US
CHMMF

0 Comments

Share your thoughts

FAQ

What is CHMMD stock price today?▼
The current price of CHMMD is $0.10 USD — it has increased by +0% in the past 24 hours. Watch CHMMD stock price performance more closely on the chart.
What is CHMMD stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange CHMMD stocks are traded under the ticker CHMMD.
What is CHMMD market cap?▼
Today CHMMD has the market capitalization of 410.88M
When is the next CHMMD earnings date?▼
CHMMD is going to release the next earnings report on August 28, 2026.
What were CHMMD earnings last quarter?▼
CHMMD earnings for the last quarter are -0.16 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CHMMD revenue for the last year?▼
CHMMD revenue for the last year amounts to 2.61M USD.
What is CHMMD net income for the last year?▼
CHMMD net income for the last year is -6.75M USD.
In which sector is CHMMD located?▼
CHMMD operates in the Other sector.
When did CHMMD complete a stock split?▼
The last stock split for CHMMD was on April 22, 2026 with a ratio of 1:100.
Where is CHMMD headquartered?▼
CHMMD is headquartered in Carlton, United States.